Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity - PubMed
a month ago
- #immunotherapy
- #radiotherapy
- #AAV
- Radiotherapy (RT) enhances immune response against cancer but often induces immunosuppressive factors.
- AAV-based platform designed to deliver immunostimulatory cytokines via an interferon-inducible promoter.
- Inducible IL-12 (AAV-iIL12) achieves efficient cytokine production without significant toxicity.
- Combination of RT and AAV-iIL12 creates an immunostimulatory tumor microenvironment (TME).
- The approach generates robust local and systemic antitumor responses, overcoming immune evasion.
- The method is efficient and safe for cancer treatment.